Shinil Pharmaceutical KRX:012790KOSDAQ
신일제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Shinil Pharmaceutical reported operating profit of ₩2.3bn. Shinil Pharmaceutical (신일제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Shinil Pharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | – | – | ₩2.3bn | ₩2.2bn |
| Q1 2026 | ₩20.9bn | +8.4% | ₩1.3bn margin 6.4% | ₩1.4bn |
| Q4 2025 derived | ₩21.1bn | -1.9% | −₩424m margin −2.0% | ₩133m |
| Q3 2025 | ₩20.6bn | -0.0% | ₩2.7bn margin 12.9% | ₩2.6bn |
| Q2 2025 | ₩19.6bn | -20.2% | ₩3.2bn margin 16.2% | ₩2.8bn |
| Q1 2025 | ₩19.2bn | -15.5% | ₩2.0bn margin 10.2% | ₩2.0bn |
| Q4 2024 derived | ₩21.5bn | -9.5% | ₩4.0bn margin 18.8% | ₩3.9bn |
| Q3 2024 | ₩20.6bn | -18.9% | ₩3.0bn margin 14.6% | ₩2.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Shinil Pharmaceutical top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Shinil Pharmaceutical news Korean headlines
No articles yet.